- Home
- CATX vs CGEN Comparison
CATX vs CGEN Comparison
Compare CATX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- CGEN
- Stock Information
- Founded
- CATX 1983
- CGEN 1993
- Country
- CATX United States
- CGEN Israel
- Employees
- CATX N/A
- CGEN N/A
- Industry
- CATX Medical/Dental Instruments
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CATX Health Care
- CGEN Health Care
- Exchange
- CATX Nasdaq
- CGEN Nasdaq
- Market Cap
- CATX 183.2M
- CGEN 149.6M
- IPO Year
- CATX N/A
- CGEN 2000
- Fundamental
- Price
- CATX $2.14
- CGEN $1.46
- Analyst Decision
- CATX Strong Buy
- CGEN Strong Buy
- Analyst Count
- CATX 11
- CGEN 1
- Target Price
- CATX $15.30
- CGEN $4.00
- AVG Volume (30 Days)
- CATX 562.0K
- CGEN 286.0K
- Earning Date
- CATX 03-26-2025
- CGEN 03-04-2025
- Dividend Yield
- CATX N/A
- CGEN N/A
- EPS Growth
- CATX N/A
- CGEN N/A
- EPS
- CATX N/A
- CGEN N/A
- Revenue
- CATX $1,454,000.00
- CGEN $27,864,000.00
- Revenue This Year
- CATX N/A
- CGEN $22.94
- Revenue Next Year
- CATX $1.15
- CGEN $15.88
- P/E Ratio
- CATX N/A
- CGEN N/A
- Revenue Growth
- CATX 1.40
- CGEN N/A
- 52 Week Low
- CATX $2.01
- CGEN $1.35
- 52 Week High
- CATX $19.10
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- CATX 31.85
- CGEN 32.02
- Support Level
- CATX $2.32
- CGEN $1.50
- Resistance Level
- CATX $2.62
- CGEN $1.65
- Average True Range (ATR)
- CATX 0.19
- CGEN 0.07
- MACD
- CATX -0.01
- CGEN 0.00
- Stochastic Oscillator
- CATX 16.25
- CGEN 12.50
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.